Fig. 4: Treatments interfering with HAS3 and CD44 combined with autophagy inhibitors exert synergistic effects on glioma cell viability and autophagy levels. | Cell Death & Disease

Fig. 4: Treatments interfering with HAS3 and CD44 combined with autophagy inhibitors exert synergistic effects on glioma cell viability and autophagy levels.

From: Interfering with hyaluronic acid metabolism suppresses glioma cell proliferation by regulating autophagy

Fig. 4

A Relative levels of the P62 and MAP1LC3B proteins in U251 glioma cells transfected with the HAS3 siRNA or cultured with a CD44 antibody, followed by treatment with CQ (30 μmol/L) for 48 h. B Viability of U251 glioma cells transfected with the HAS3 siRNA or cultured with a CD44 antibody, followed by treatment with CQ (30 μmol/L) for 48 h. C–D Levels of the Ki67 protein in U251 glioma cells were detected using immunofluorescence staining after transfection with the HAS3 siRNA or culture with a CD44 antibody, followed by treatment with CQ (30 μmol/L) for 48 h. Scale bar: 50 μm. The data are presented as the mean ± SD; *P < 0.05, **P < 0.01, and ***P < 0.001, ****P < 0.0001.

Back to article page